Inversago Pharma Inc. clinical trials
Acquired by Novo Nordisk A/S, Sep 11, 2023 · source ↗
The registry lists 4 studies whose lead sponsor is Inversago Pharma Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 11, 2025.
Before and after it joined Novo Nordisk A/S
- First submitted before Inversago Pharma Inc. became part of Novo Nordisk A/S
- 4
- First submitted after Inversago Pharma Inc. became part of Novo Nordisk A/S
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Inversago Pharma Inc.4 studies
Something wrong with this grouping? Tell us on the Novo Nordisk A/S page.
Studies
Recruiting first, then most recently updated. Showing 4 of 4. All Novo Nordisk A/S studies →
- Phase 2 Study of INV-202 in Patients With Diabetic Kidney DiseaseCompletedNCT05514548Phase 2
Sponsor listed in the registry: Inversago Pharma Inc. · First submitted before Inversago Pharma Inc. became part of Novo Nordisk A/S
- Study of INV-202 in Patients With Obesity and Metabolic SyndromeCompletedNCT05891834Phase 2
Sponsor listed in the registry: Inversago Pharma Inc. · First submitted before Inversago Pharma Inc. became part of Novo Nordisk A/S
- Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female SubjectsCompletedNCT04531150Phase 1
Sponsor listed in the registry: Inversago Pharma Inc. · First submitted before Inversago Pharma Inc. became part of Novo Nordisk A/S
- A Study to Explore the PK and PD of INV-202 in Metabolic SyndromeCompletedNCT05282446Phase 1
Sponsor listed in the registry: Inversago Pharma Inc. · First submitted before Inversago Pharma Inc. became part of Novo Nordisk A/S